Scientists Come Closer to Reversing Aging by Generating Young Mesenchymal Stem Cells from Blood of a 75-Year-Old Donor

科学家通过从75岁捐献者的血液中产生年轻的间充质干细胞，更接近逆转衰老

MIAMI BEACH, Fla., May 23, 2024 /PRNewswire/ -- Immorta Bio Inc, a science-based Life Extension company has announced patent filing on successful treatment of the carbon tetrachloride model of liver failure using its PMSC-11 stem cell therapy. Data disclosed in its filed patent demonstrates PMSC-11 potently suppresses liver damage as detected by preserving albumin production and blocking catastrophic rises in liver enzymes which are typical in liver failure.  Importantly, the administration of the PMSC-11 stem cell product induced a potent increase in a totally unexpected cytokine whose expression in some publications has been correlated with accelerated recovery from hepatic failure..

佛罗里达州迈阿密海滩，2024年5月23日/PRNewswire/--一家以科学为基础的生命延长公司Immorta Bio Inc宣布申请专利，使用其PMSC-11干细胞疗法成功治疗四氯化碳肝衰竭模型。在其申请专利中披露的数据表明，PMSC-11通过保留白蛋白的产生和阻断肝衰竭中典型的肝酶的灾难性升高来有效抑制肝损伤。重要的是，PMSC-11干细胞产物的给药诱导了一种完全出乎意料的细胞因子的有效增加，这种细胞因子在某些出版物中的表达与肝衰竭的加速恢复有关。。

'The PMSC-11 product is a personalized mesenchymal stem cell that is generated to possess a significantly younger biological age than the patient,' said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. 'The PMSC-11 cells, utilized in the experiments reported today, demonstrated safety as well as therapeutic efficacy, supporting continued development of this 'First in Class' Stem Cell Therapy for liver failure.'.

Immorta Bio总裁兼首席科学官托马斯·伊希姆（Thomas Ichim）博士说：“PMSC-11产品是一种个性化的间充质干细胞，其产生的生物学年龄比患者年轻得多。PMSC-11细胞在今天报道的实验中使用，证明了其安全性和治疗效果，支持了这种“一流的”肝衰竭干细胞疗法的持续发展。”。

'Liver Failure is the fifth leading cause of death world-wide with no therapeutic options besides transplantation. We are conducting pre-clinical experiments in animals using human cells to demonstrate safety and efficacy of these cells before applying to the FDA to begin clinical trials,' said Dr. Vlad Bykoriz, Chief Medical Officer of Immorta Bio. .

“肝衰竭是全球第五大死亡原因，除移植外没有治疗选择。Immorta Bio首席医学官弗拉德·拜科里兹（VladBykoriz）博士说，我们正在使用人类细胞对动物进行临床前实验，以证明这些细胞的安全性和有效性，然后再向FDA申请开始临床试验。

Stem cells have previously been demonstrated to possess some therapeutic effects on liver failure, however allogeneic stem cells, that have been mostly used so far, are eventually rejected by the patient. And autologous adult stem cells are limited in numbers, and often dysfunctional because of preexisting conditions.

先前已经证明干细胞对肝衰竭具有一些治疗作用，但是迄今为止主要使用的同种异体干细胞最终被患者拒绝。自体成体干细胞数量有限，由于先前存在的条件，通常功能失调。

The PMSC product overcomes some of the shortcomings of existing stem cell therapeutics. These cells are patient specific, 'biologically younger', and can be created in unlimited numbers because they are derived from the embryonic-like PRC..

PMSC产品克服了现有干细胞疗法的一些缺点。这些细胞是患者特有的，“生物学上更年轻”，并且可以无限数量地产生，因为它们来源于类似胚胎的PRC。。

'Our vision of significant life extension is based on revivifying aged or damaged organs,' said Dr. Boris Reznik, CEO and Chairman of the Company. 'We generate 'Amenable Stem Cells' (ASC) from a tablespoon of patient's blood and utilize our proprietary technology to transform these ASC into 'Personalized Regenerative Cells' (PRC).  The PRC are very similar to the immortal embryonic stem cells and are generated by 'reverse differentiation' of the ASC from the patient's blood.  These PRC should allow for creation and introduction of cells for any tissue or organ whose regeneration is desired.

该公司首席执行官兼董事长鲍里斯·雷兹尼克（BorisReznik）博士说，我们对延长寿命的愿景是基于使衰老或受损的器官恢复活力我们从一汤匙患者的血液中产生“合适的干细胞”（ASC），并利用我们的专有技术将这些ASC转化为“个性化再生细胞”（PRC）。PRC与永生胚胎干细胞非常相似，是由患者血液中ASC的“反向分化”产生的。这些PRC应该允许为需要再生的任何组织或器官创建和引入细胞。

Today's announcement provides a glimpse into the potential power of our Stem Cell Revivify™ path to organ and eventually whole-body rejuvenation.'.

今天的公告让我们瞥见了我们的干细胞复兴™途径对器官和最终全身复兴的潜在力量。”。

About Immorta Bio:

关于不朽生物：

Immorta Bio is a biotechnology company developing efficient and practical personalized stem cell platforms aimed at Treating Diseases of Aging and Treating Aging as Disease™. Our objective is to rejuvenate the old and damaged organs to the healthy state, achieving, what we call, Stem Cell Revivify™.

Immorta Bio是一家开发高效实用的个性化干细胞平台的生物技术公司，旨在治疗衰老疾病和将衰老视为疾病™。我们的目标是使衰老和受损的器官恢复到健康状态，实现我们所称的干细胞复兴™。

By solving the problem of diseases of aging, we can potentially dramatically increase our patients' longevity..

通过解决衰老疾病的问题，我们有可能大大延长患者的寿命。。

For more information, please visit the Immorta Bio website at https://www.immortabio.com or find them on X at https://twitter.com/ImmortaBio.

有关更多信息，请访问Immorta Bio网站https://www.immortabio.com或者在X上找到他们https://twitter.com/ImmortaBio.

Media Contacts:

媒体联系人：

Dr. Boris Reznik

Boris Reznik博士

Immorta Bio

生物导入

https://www.immortabio.com

https://www.immortabio.com

+1 305-632-2939

+1 305-632-2939

@immortabio

@不动产生物

View original content to download multimedia:https://www.prnewswire.com/news-releases/immorta-bio-inc-a-longevity-company-announces-a-significant-breakthrough-in-treatment-of-liver-failure-302154227.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/immorta-bio-inc-a-longevity-company-announces-a-significant-breakthrough-in-treatment-of-liver-failure-302154227.html

SOURCE Immorta Bio, Inc.

资料来源：Immorta生物公司。